Results
|
1.
|
|
|
2.
|
International Expert Consensus on Switching Platelet P2Y<sub>12</sub> Receptor-Inhibiting Therapies. MedStar authors:
Year: 2017
Citation: - Circulation. 136(20):1955-1975, 2017 Nov 14
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Alexopoulos D, Angiolillo DJ, Aradi D, Bhatt DL, Bonello L, Cuisset T, De Luca L, Franchi F, Gurbel PA, Hochholzer W, James S, Mehran R, Montalescot G, Price MJ, Rollini F, Schneider DJ, Sibbing D, So DYF, Storey RF, Tantry US, Trenk D, Valgimigli M, Waksman R, Wang TY
|
|
3.
|
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(12):1600-1609, 2017 Dec
Institution: - MedStar Franklin Square Hospital
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J
|